Versant Venture Management

Latest statistics and disclosures from Versant Venture Management's latest quarterly 13F-HR filing:

  • Top 5 stock holdings are CRSP, PASG, GRTS, ALGS, CRNX, and represent 83.53% of Versant Venture Management's stock portfolio.
  • Reduced shares in these 2 stocks: GRTS, CRSP.
  • Versant Venture Management was a net seller of stock by $-5.9M.
  • Versant Venture Management has $242M in assets under management (AUM), dropping by -19.98%.
  • Central Index Key (CIK): 0001560009

Tip: Access up to 7 years of quarterly data

Positions held by Versant Venture Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Portfolio Holdings for Versant Venture Management

Companies in the Versant Venture Management portfolio as of the September 2021 quarterly 13F filing

Company (Ticker) Portfolio Weight Valued At Change in Shares Share Count Share Price
CRISPR Therapeutics Common Shares (CRSP) 23.1 $56M 499k 111.93
Passage Bio Common Stock (PASG) 20.5 $49M 5.0M 9.96
Gritstone Oncology Common Stock (GRTS) 17.9 $43M -9% 4.0M 10.80
Aligos Therapeutics Common Stock (ALGS) 14.9 $36M 2.3M 15.51
Crinetics Pharmaceuticals Common Stock (CRNX) 7.2 $17M 821k 21.05
Akero Therapeutics Common Stock (AKRO) 5.7 $14M 618k 22.35
Adverum Biotechnologies Common Stock (ADVM) 4.6 $11M 5.1M 2.17
Aprea Therapeutics Common Stock (APRE) 2.7 $6.4M 1.3M 5.11
Flexion Therapeutics Common Stock (FLXN) 2.5 $6.1M 1.0M 6.10
CymaBay Therapeutics Common Stock (CBAY) 0.8 $2.0M 544k 3.65
Clovis Oncology Common Stock (CLVS) 0.2 $454k 102k 4.46

Past Filings by Versant Venture Management

SEC 13F filings are viewable for Versant Venture Management going back to 2014

View all past filings